Researchers from Eurofarma Laboratorios SA and Universidade Federal do Rio de Janeiro – Macae havs synthesized histone deacetylase 6 (HDAC6) inhibitors reported to be potentially useful for the treatment of cancer.
Heart failure with preserved ejection fraction (HFpEF) is a complex disease with limited therapeutic options. Protein histone deacetylase 6 (HDAC6) is known to be involved in several biological processes, such as autophagy or inflammation, among others, but its impact on HFpEF has not been well evaluated to date.
Researchers at Keimyung University and its medical school generated various candidate quinazolin-4-one derivatives, the most promising of which inhibited HDAC6 with an IC50 of 17 nM, 19-fold more strongly than it inhibited the off-target deacetylase HDAC1.
Suzhou Genhouse Bio Co. Ltd. has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, asthma, Alzheimer’s disease, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.
Inhibiting histone deacetylase 6 (HDAC6) has therapeutic potential against several neurodegenerative disorders. A collaboration including researchers from Eikonizo Therapeutics Inc., spanning the U.K., U.S. and France, developed EKZ-438, which has shown strong potential against amyotrophic lateral sclerosis and frontotemporal dementia in preclinical studies.
Tumor immunotherapy has become a standard of care for treating various cancers, with immune checkpoint inhibitors targeting the PD-L1/PD-1 axis proving particularly effective. While PD-L1 expression on tumor cells is a predictive biomarker for therapeutic response, emerging evidence highlights the importance of PD-L1 expression on myeloid cells, such as monocytes and dendritic cells (DCs), in shaping the tumor microenvironment and influencing the success of checkpoint blockade.
Eight months after announcing the $18.5 million first tranche of its series A, Augustine Therapeutics has closed the oversubscribed round at $85 million and is now ready to begin clinical development of its novel histone deacetylase-6 (HDAC6) inhibitors.
Eight months after announcing the $18.5 million first tranche of its series A, Augustine Therapeutics has closed the oversubscribed round at $85 million and is now ready to begin clinical development of its novel histone deacetylase-6 (HDAC6) inhibitors.
Melanoma is responsible for about 80% of skin cancer deaths worldwide, particularly in cases with metastasis. Melanoma shows resistance to standard therapy and the search for novel treatment options is a medical need.
